These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 26279289)
1. T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen. Hartling HJ; Birch C; Gaardbo JC; Hove M; Trøseid M; Clausen MR; Gerstoft J; Ullum H; Nielsen SD APMIS; 2015 Oct; 123(10):903-11. PubMed ID: 26279289 [TBL] [Abstract][Full Text] [Related]
2. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Kwo P; Gane EJ; Peng CY; Pearlman B; Vierling JM; Serfaty L; Buti M; Shafran S; Stryszak P; Lin L; Gress J; Black S; Dutko FJ; Robertson M; Wahl J; Lupinacci L; Barr E; Haber B Gastroenterology; 2017 Jan; 152(1):164-175.e4. PubMed ID: 27720838 [TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518 [TBL] [Abstract][Full Text] [Related]
5. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of chronic hepatitis viral C: new associations]. Ouzan D Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659 [TBL] [Abstract][Full Text] [Related]
7. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579 [TBL] [Abstract][Full Text] [Related]
9. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. Méndez-Lagares G; Lu D; Chen C; Terrault N; Segal MR; Khalili M; Monto A; Shen H; Manos MM; Lanier LL; Ryan JC; McCune JM; Hartigan-O'Connor DJ J Immunol; 2018 Feb; 200(3):1124-1132. PubMed ID: 29263212 [TBL] [Abstract][Full Text] [Related]
10. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin. Neau D; Galpérine T; Legrand E; Pitard V; Neau-Cransac M; Moreau JF; Ragnaud JM; Dupon M; Fleury H; Lafon ME HIV Med; 2003 Apr; 4(2):120-6. PubMed ID: 12702132 [TBL] [Abstract][Full Text] [Related]
11. HCV-specific CD8+ cell detection at week 12 of chronic hepatitis C treatment with PEG-interferon-α2b/ribavirin correlates with infection resolution. Larrubia JR; Lokhande MU; Moreno-Cubero E; García-Garzón S; Miquel J; Parra-Cid T; González-Praetorious A; Perna C; Lázaro A; Sanz-de-Villalobos E Cell Immunol; 2013; 286(1-2):31-8. PubMed ID: 24287274 [TBL] [Abstract][Full Text] [Related]
12. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. Coppola N; Pisaturo M; Sagnelli C; Sagnelli E; Angelillo IF PLoS One; 2014; 9(4):e94542. PubMed ID: 24728219 [TBL] [Abstract][Full Text] [Related]
13. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lawitz E; Gane E; Pearlman B; Tam E; Ghesquiere W; Guyader D; Alric L; Bronowicki JP; Lester L; Sievert W; Ghalib R; Balart L; Sund F; Lagging M; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B Lancet; 2015 Mar; 385(9973):1075-86. PubMed ID: 25467591 [TBL] [Abstract][Full Text] [Related]
15. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Buti M; Gordon SC; Zuckerman E; Lawitz E; Calleja JL; Hofer H; Gilbert C; Palcza J; Howe AY; DiNubile MJ; Robertson MN; Wahl J; Barr E; Forns X Clin Infect Dis; 2016 Jan; 62(1):32-6. PubMed ID: 26371152 [TBL] [Abstract][Full Text] [Related]
16. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864 [TBL] [Abstract][Full Text] [Related]
17. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir. Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience. Alsaran K; Sabry A; Shaheen N Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669 [TBL] [Abstract][Full Text] [Related]
19. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients. Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554 [TBL] [Abstract][Full Text] [Related]
20. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]